Fate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions
October 05 2016 - 8:00AM
Protects Cellular Composition of Lead
Immunotherapy Product Candidate ProTmune™
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company
dedicated to the development of programmed cellular immunotherapies
for cancer and immune disorders, announced today that the U.S.
Patent and Trademark Office issued U.S. Patent No. 9,452,186
covering enhanced hematopoietic stem cell compositions. This
newly-issued patent expands the Company’s significant intellectual
property position covering ex vivo small molecule modulation of
hematopoietic stem cells, which includes compositions and methods
for enhanced lentiviral transduction and engraftment in the field
of hematopoietic cell transplantation. The Company also has filed
corresponding patent applications to seek similar patent protection
for its hematopoietic stem cell compositions in key markets
throughout the world, including Europe and Japan.
“Fate Therapeutics has pioneered the ex vivo use of small
molecules, including prostaglandin pathway agonists, to modulate
the safety and efficacy of hematopoietic cells prior to patient
administration,” said Scott Wolchko, President and Chief Executive
Officer of Fate Therapeutics. “The issuance of this composition of
matter patent, which covers the cellular composition of our lead
product candidate ProTmune, validates that our ex vivo modulation
approach can generate proprietary cellular immunotherapies. We
believe this approach, which is backed by our extensive
intellectual property, is broadly applicable to the development of
hematopoietic cell therapies with novel biological properties and
enhanced therapeutic functionality.”
This most recent patent, which expires in 2032, specifically
covers compositions of hematopoietic stem and progenitor cells with
increased CXCR4 gene expression and methods of increasing
engraftment and reconstitution in patients by administering
CXCR4-enhanced hematopoietic stem cells. CXCR4 signaling has been
proven to play a pivotal role in the homing of hematopoietic stem
and progenitor cells to the bone marrow in vivo and is critical to
realizing the curative potential of hematopoietic cell
transplantation. Importantly, these newly patented compositions and
methods are independent of the specific modulators used to enhance
the cells’ biological properties and therapeutic function.
About ProTmune™ProTmune™ is an investigational
programmed cellular immunotherapy undergoing clinical development
for the prevention of acute graft-versus-host disease and
cytomegalovirus infection in patients undergoing allogeneic
hematopoietic cell transplantation. ProTmune is manufactured by
modulating a donor-sourced, mobilized peripheral blood graft ex
vivo with two small molecules (FT1050 and FT4145) to enhance the
biological properties and therapeutic function of the graft’s
immune cells. The programmed mobilized peripheral blood graft is
administered to a patient as a one-time intravenous infusion.
ProTmune has been granted Orphan Drug and Fast Track Designations
by the U.S. Food and Drug Administration.
About Fate Therapeutics, Inc.Fate Therapeutics
is a biopharmaceutical company dedicated to the development of
programmed cellular immunotherapies for cancer and immune
disorders. The Company’s hematopoietic cell therapy pipeline is
comprised of NK- and T-cell immuno-oncology programs, including
off-the-shelf product candidates derived from engineered induced
pluripotent cells, and immuno-regulatory programs, including
product candidates to prevent life-threatening complications in
patients undergoing hematopoietic cell transplantation and to
promote immune tolerance in patients with autoimmune disease. Its
adoptive cell therapy programs are based on the Company’s novel ex
vivo cell programming approach, which it applies to modulate the
therapeutic function and direct the fate of immune cells. Fate
Therapeutics is headquartered in San Diego, CA. For more
information, please visit www.fatetherapeutics.com.
Forward-Looking Statements This release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements regarding the scope and strength of the Company’s
intellectual property portfolio and the therapeutic potential of
programmed immunotherapies. These and any other forward-looking
statements in this release are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risk that any of the Company’s patents
may be challenged and that such a challenge may be successful,
resulting in loss of any such patent or loss or reduction in the
scope of one or more of the claims of a challenged patent, the risk
that results observed in prior studies, including preclinical
studies of its product candidates, will not be observed in ongoing
or future studies involving these product candidates, the risk that
the Company may cease or delay preclinical or clinical development
activities for any of its existing or future product candidates for
a variety of reasons, and the risk that product candidates
developed by the Company may not provide the anticipated
therapeutic benefits. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the risks and uncertainties
detailed in the Company’s periodic filings with the Securities and
Exchange Commission, including but not limited to the Company’s
most recently filed periodic report, and from time to time the
Company’s other investor communications. Fate Therapeutics is
providing the information in this release as of this date and does
not undertake any obligation to update any forward-looking
statements contained in this release as a result of new
information, future events or otherwise.
Contact:
Jesse Baumgartner
Stern Investor Relations, Inc.
212.362.1200
jesse@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Apr 2024 to May 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From May 2023 to May 2024